Table of Contents
Executive Summary — 5
SWOT
Analysis — 6
Lithuania Pharmaceuticals And Healthcare
Industry SWOT — 6
Political SWOT — 7
Economic SWOT — 7
Business Environment
SWOT — 8
Pharmaceutical Business Environment
Ratings — 9
Table: Regional Pharma Business Environment
Ratings — 9
Limits of Potential
Returns — 10
Risk to Realisation of
Returns — 11
Lithuania – Market
Summary — 12
Regulatory Regime — 13
Regional Collaboration — 14
Recent EU-Wide Regulatory
Developments — 14
Intellectual Property
Developments — 15
Pricing Regime — 16
Reimbursement Regime — 16
Industry
Developments — 19
Epidemiology — 19
Healthcare System — 20
Healthcare
Funding — 21
Healthcare Insurance — 22
Corruption — 22
Pharmaceutical
Industry — 22
Table: Drugmakers, Distributors And
Retailers Active In The Baltic States, Q207 — 23
Recent
Pharmaceutical Industry Developments — 24
Pharmaceutical
Wholesale and Distribution — 26
Pharmaceutical
Retail — 27
Biotechnology — 28
Clinical Trials — 30
Medical
Devices — 30
Industry Forecast
Scenario — 31
Overall Market
Forecast — 31
Table: Lithuania – Drug Expenditure
Indicators, Historical Data and Forecasts — 32
Key Growth
Factors – Industry — 33
Table: Lithuania –
Healthcare Expenditure Indicators, Historical Data and
Forecasts — 34
Key Growth Factors –
Macroeconomic — 35
Table: Lithuania – Economic
Activity — 37
Prescription Market
Forecast — 38
Table: Lithuania – Prescription Market
Indicators, Historical Data and Forecasts (LTLmn unless otherwise
stated) — 39
Patented Drug Market
Forecast — 40
Table: Lithuania – Patented Drug
Market Indicators, Historical Data And Forecasts — 41
Generic Drug Market Forecast — 42
Table: Lithuania –
Generics Market Indicators, Historical Data And
Forecasts — 42
OTC Drug Market
Forecast — 43
Table: Lithuania – OTC Market
Indicators, Historical Data And Forecasts (LTLmn unless otherwise
stated) — 44
Export/Import
Forecasts — 45
Table: Lithuania – Pharmaceutical
Trade, Historical Data And Forecasts (US$mn) — 45
Other
Healthcare Data Forecasts — 46
Table: Lithuania - Other
Healthcare Indicators, Historical Data And Forecasts — 46
Key Risks to BMI’s Forecast Scenario — 47
Competitive Landscape — 48
Company
Monitor — 49
Multinational Company
Profiles — 49
GlaxoSmithKline — 49
Pfizer — 51
Novartis — 53
Merck &
Co — 54
Sanofi-Aventis — 55
Indigenous
Company Profiles — 57
Valentis — 57
Sanitas — 59
Sicor Biotech — 63
Country Snapshot: Lithuania Demographic Data — 65
Section
1: Population — 65
Table: Demographic Indicators,
2005-2030 — 65
Table: Rural/Urban Breakdown,
2005-2030 — 66
Section 2: Education And
Healthcare — 66
Table: Education,
2002-2005 — 66
Table: Vital Statistics,
2005-2030 — 66
Section 3: Labour Market and Spending
Power — 67
Table: Employment Indicators,
2001-2006 — 67
Table: Consumer Expenditure, 2000-2012
(US$) — 68
Table: Average Annual Wages,
2000-2012 — 68
BMI Forecast
Modelling — 69
How We Generate Our Pharmaceutical Industry
Forecasts — 69
Pharmaceutical Business Environment Ratings
Methodology — 70
Ratings Overview — 70
Table: Pharmaceutical Business Environment Indicators — 71
Weighting — 72
Table: Weighting Of
Components — 72
Sources — 72
| 
View Cart
